AgomAb Therapeutics NV (AGMB) vs Atea Pharmaceuticals (AVIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($454.1 million vs $413.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | AVIR |
|---|---|---|
| Share price | $9.22 | $5.16 |
| Market cap | $454.07M | $413.46M |
| 1-day change | +4.77% | +2.89% |
| YTD return | — | +44.40% |
| 1-year return | — | +66.29% |
| 5-year return | — | -86.88% |
| EPS (TTM) | $-2.08 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $6.45 |
| 52-week low | $7.97 | $2.87 |
| Distance from 52-week high | -48.26% | -20.08% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +308.57% | +82.74% |
| Average volume | 139.21K | 298.98K |
| Shares outstanding | 49.25M | 80.20M |
| Employees | 62 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
AGMB vs AVIR FAQ
Which is bigger, AgomAb Therapeutics NV or Atea Pharmaceuticals?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $454.07M compared with $413.46M for Atea Pharmaceuticals (AVIR).
Are AgomAb Therapeutics NV and Atea Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for Atea Pharmaceuticals.